Similarly, treprostinil, through cAMP-C/EBP-α p42-p21 (WAf1/Cip1) signaling, reduces arterial wall remodeling which benefits patients with PAH (49–51). This evidence concerns the gene CDKN1A and pulmonary arterial hypertension.